Sort
30,917 grants matching “tumor microenvironment”
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$1,004,043Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.
$1,003,836Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · U01 · FY2024 · CA
Making cancer precision medicine real: bottlenecks and opportunities
$1,003,803Todd R. Golub · Broad Institute, Inc. · R35 · FY2022 · CA
Making cancer precision medicine real: bottlenecks and opportunities
$1,003,799Todd R. Golub · Broad Institute, Inc. · R35 · FY2023 · CA
Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma
$1,002,741Richard Klinghoffer · Presage Biosciences, Inc. · R44 · FY2017 · CA
Biology of Mammary Gland Development and Tumorigenesis
$1,002,711Gilbert Smith · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
$1,002,483Valerie Humblet · Collagen Medical, Llc · R44 · FY2017 · CA
Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response
$1,002,287Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2024 · CA
MECHANISM BASED RADIOTHERAPY
$1,002,188Johns Hopkins University · P01 · FY2003 · CA
Roles of tumor suppressors (TSs) in metastatic progression
$1,001,789Li Yang · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Myeloid TGFbeta signaling in breast cancer metastasis
$1,001,789Li Yang · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
$1,001,029Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2024 · CA
The Cancer Target Discovery and Development Network at UCSF
$1,000,618Michael T McManus · University Of California, San Francisco · U01 · FY2019 · CA
Commercialization of ASONEP for the Treatment of Cancer
$1,000,000Roger Allen Sabbadini · Lpath Therapeutics, Inc. · R44 · FY2009 · CA
Non-invasive staging of Metastasis by Precision MRI
$1,000,000Yiting Xu · Inlighta Biosciences, Llc · R44 · FY2023 · CA
Commercialization of ASONEP for the Treatment of Cancer
$1,000,000Roger Allen Sabbadini · Lpath Therapeutics, Inc. · R44 · FY2010 · CA
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2022 · CA
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2023 · CA
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2021 · CA
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2024 · CA
Optimization of a clinical stage nanoparticle drug delivery platform
$1,000,000Bob D. Brown · Dicerna Pharmaceuticals, Inc. · R44 · FY2016 · CA
Commercialization of ASONEP for the Treatment of Cancer
$1,000,000Roger Allen Sabbadini · Lpath Therapeutics, Inc. · R44 · FY2011 · CA
Improving the Efficacy of Dendritic Cell Vaccines
$999,999Jacques F Banchereau · Baylor Research Institute · P01 · FY2006 · CA
Spatial and single cell analysis of tumor microenvironment by seqFISH+
$999,999Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2021 · CA